These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31486689)

  • 21. Antiglaucoma carbonic anhydrase inhibitors: a patent review.
    Masini E; Carta F; Scozzafava A; Supuran CT
    Expert Opin Ther Pat; 2013; 23(6):705-16. PubMed ID: 23627893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on the role of alpha-agonists in glaucoma management.
    Arthur S; Cantor LB
    Exp Eye Res; 2011 Sep; 93(3):271-83. PubMed ID: 21524649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications.
    Higginbotham EJ; Diestelhorst M; Pfeiffer N; Rouland JF; Alm A
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S133-40. PubMed ID: 12204710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switch to latanoprost monotherapy from combined treatment with beta-antagonist and other antiglaucoma agents in patients with glaucoma or ocular hypertension.
    Ito K; Goto R; Matsunaga K; Sugimoto K; Uji Y
    Jpn J Ophthalmol; 2004; 48(3):276-80. PubMed ID: 15175922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical treatment of normal tension glaucoma.
    Hoyng PF; Kitazawa Y
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S116-24. PubMed ID: 12204707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
    Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging drugs for ocular hypertension.
    Lee AJ; Goldberg I
    Expert Opin Emerg Drugs; 2011 Mar; 16(1):137-61. PubMed ID: 21352074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short- and long-term safety of glaucoma drugs.
    Schuman JS
    Expert Opin Drug Saf; 2002 Jul; 1(2):181-94. PubMed ID: 12904152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
    Inoue T; Tanihara H
    Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018).
    Angeli A; Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):793-803. PubMed ID: 31462124
    [No Abstract]   [Full Text] [Related]  

  • 32. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.
    Holló G; Topouzis F; Fechtner RD
    Expert Opin Pharmacother; 2014 Aug; 15(12):1737-47. PubMed ID: 24998246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changing paradigms in the medical treatment of glaucoma.
    Soltau JB; Zimmerman TJ
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S2-5. PubMed ID: 12204696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension.
    Frampton JE; Perry CM
    Drugs Aging; 2006; 23(12):977-95. PubMed ID: 17154662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
    Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
    Katz G; Dubiner H; Samples J; Vold S; Sall K
    JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical treatment of glaucoma: established and emerging pharmacology.
    Dikopf MS; Vajaranant TS; Edward DP
    Expert Opin Pharmacother; 2017 Jun; 18(9):885-898. PubMed ID: 28480761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma.
    Crooke A; Huete-Toral F; Martínez-Águila A; Martín-Gil A; Pintor J
    J Pharmacol Exp Ther; 2013 Jul; 346(1):138-45. PubMed ID: 23591996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs.
    Sakanaka K; Kawazu K; Tomonari M; Kitahara T; Nakashima M; Nishida K; Nakamura J; Sasaki H; Higuchi S
    Biol Pharm Bull; 2008 Aug; 31(8):1590-5. PubMed ID: 18670094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.